ReviewPharmaceuticals (Basel, Switzerland)2021

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia.

Laura Jimbu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.